Targeting VEGFRs, particularly VEGFR2, has provided clinical benefits for patients suffering from angiogenesis-dependent disorders, such as cancer, but this treatment has been confined to patients with cancer and is not yet available for the treatment of eye diseases (http://www.angio.org/ua.php). This evidence concerns the gene KDR and cancer.